Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Athenahealth Appoints Former CVS Executive Tom Cowhey as New CFO

Athenahealth, a leading health IT firm and electronic health record vendor, has announced the appointment of Tom Cowhey as its new Chief Financial Officer. The move comes as part of a series of leadership changes in the healthcare industry, reflecting the dynamic nature of the sector and its ongoing financial challenges.

NoahAI News5/28/2025

iTeos Therapeutics Winds Down Operations Following TIGIT Setback

In a surprising turn of events, iTeos Therapeutics has announced its decision to wind down operations, just two weeks after terminating its partnership with GlaxoSmithKline (GSK) on the TIGIT inhibitor belrestotug. The Belgium-based biotech company plans to sell its assets and return a significant portion of its substantial cash reserves to investors.

NoahAI News5/28/2025

GLP-1 Prescriptions for Weight Loss Soar Amid Market Challenges and Opportunities

The pharmaceutical industry is witnessing a dramatic surge in the adoption of GLP-1 (glucagon-like peptide-1) drugs for weight loss, despite recent supply challenges and high costs. This trend is reshaping the obesity treatment landscape and creating significant opportunities for drug manufacturers.

NoahAI News5/28/2025

PeaceHealth Announces Workforce Reduction and Hiring Freeze Amid Healthcare Industry Challenges

PeaceHealth, a prominent health system operating in Washington, Oregon, and Alaska, has revealed plans to reduce its workforce by 1% and implement a freeze on nonclinical hiring through the end of 2025. This decision comes as the latest in a series of similar moves by healthcare providers across the United States, reflecting the ongoing financial pressures and market dynamics affecting the industry.

NoahAI News5/28/2025

Merck KGaA's Pimicotinib Shows Promise in Phase 3 TGCT Trial, Setting Stage for Market Competition

Merck KGaA has unveiled detailed phase 3 data for pimicotinib, its investigational treatment for tenosynovial giant cell tumor (TGCT), a rare and locally aggressive tumor type. The results, set to be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) annual meeting, demonstrate the drug's efficacy and potentially favorable safety profile, positioning it as a strong contender in the emerging TGCT market.

NoahAI News5/28/2025

Emerging Biopharma Companies Lead the Way in Clinical Trial Innovation

In a rapidly evolving pharmaceutical landscape, smaller and more agile biopharma companies are taking center stage in drug development, outpacing traditional large-scale players with their ability to meet aggressive timelines and navigate complex challenges. This shift is reshaping the industry, particularly in the realm of clinical trials, where innovative approaches to project management and supply chain logistics are becoming critical success factors.

NoahAI News5/28/2025

GSK's Antibiotic Gamble Pays Off: Tebipenem HBr Shows Promise in Phase 3 Trial

GSK's strategic $66 million investment in Spero Therapeutics' antibiotic program has yielded positive results, as tebipenem HBr demonstrates efficacy in a pivotal phase 3 trial for complicated urinary tract infections (cUTIs). The study's early termination due to meeting its primary endpoint marks a significant milestone in the development of oral treatments for drug-resistant infections.

NoahAI News5/28/2025

Biogen's Zurzuvae Strategy Evolves as OB/GYNs Take Center Stage in Postpartum Depression Treatment

Biogen's postpartum depression (PPD) drug Zurzuvae is approaching its two-year milestone since approval, with the company reporting significant shifts in its marketing strategy and prescribing patterns. Initially targeting psychiatrists, Biogen has now pivoted to focus on obstetricians and gynecologists (OB/GYNs) as the primary prescribers for this groundbreaking treatment.

NoahAI News5/28/2025

Pharmaceutical Industry Maintains R&D Momentum Despite Economic Headwinds

The global pharmaceutical industry continued to increase its research and development (R&D) investments in 2024, demonstrating resilience in the face of economic and political challenges. According to data from Evaluate Pharma, R&D spending across the sector grew by 1.5% last year, reaching a staggering $288 billion. While this growth rate represents a moderation from the 11.5% surge seen between 2022 and 2023, it underscores the industry's commitment to innovation and pipeline development.

NoahAI News5/28/2025

Lilly Expands Pain Portfolio with $1B SiteOne Acquisition, Challenging Vertex in Non-Opioid Market

Eli Lilly has announced the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, signaling a strategic move into the non-opioid pain medication market. This acquisition not only diversifies Lilly's pipeline but also positions the company to compete with Vertex Pharmaceuticals, which recently gained FDA approval for its own non-addictive pain treatment.

NoahAI News5/28/2025

Zimmer Biomet Appoints Kevin Thornal as Group President for Global Businesses and the Americas

Zimmer Biomet, a leading orthopedics device manufacturer, has announced the appointment of Kevin Thornal to the newly created position of group president for global businesses and the Americas, effective July 1. This strategic move comes as part of the company's ongoing efforts to strengthen its leadership team and drive growth in key markets.

NoahAI News5/28/2025

Pharmaceutical Industry Faces Widespread Layoffs Amid Restructuring and Pipeline Challenges

The pharmaceutical and biotech sectors continue to grapple with significant workforce reductions as companies across the industry streamline operations, reprioritize pipelines, and attempt to extend cash runways in a challenging economic environment.

NoahAI News5/28/2025

«1...62 63 64...67 »